![Rank: 8](static/image/common/star_level3.gif) ![Rank: 8](static/image/common/star_level3.gif)
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Surgical resection versus radiofrequency ablation for early recurrent hepatocellular carcinoma
Shi, Tongtonga; Xu, Chenghuia; Feng, Yueminb; Wei, Yingnanb; Lv, Huanranb; Zhu, Qiangc,a
Author Information
aDepartment of Gastroenterology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University
bDepartment of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan
cDepartment of Gastroenterology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
Received 7 April 2022 Accepted 4 May 2022
Correspondence to Qiang Zhu, MD, Department of Gastroenterology, The First Affiliated Hospital of Xinjiang Medical University, 567#, Shangde North Road, Urumqi 830017, Urumqi, China, Tel: +86 531 68777012; e-mail: [email protected]
European Journal of Gastroenterology & Hepatology: August 2022 - Volume 34 - Issue 8 - p 844-851
doi: 10.1097/MEG.0000000000002393
Buy
Abstract
Background
Surgical resection (SR) and radiofrequency ablation (RFA) are reasonable treatment options for early recurrent hepatocellular carcinoma (rHCC), but it is still uncertain which treatment is better. The purpose of this study was to compare the therapeutic effects of SR and RFA on patients with early rHCC.
Methods
This study enrolled 168 patients with early rHCC who underwent SR or RFA. The progression-free survival (PFS), overall survival (OS), and complications between the treatment groups for the total and propensity score-matched (PSM) cohorts were compared.
Results
Before PSM, the 1-, 3-, 5-year OS (94.8%, 63.0%, 36.1% vs. 93.8%, 58.5%, 35.4%, P = 0.580) and PFS (50.7%, 22.7%, 12.0% vs. 68.8%, 30.3%, 15.9%, P = 0.224) were similar in RFA group and the SR group. After PSM, the 1-, 3-, 5-year OS (95.5%, 71.1%, 53.3% vs. 95.5%, 58.0%, 42.1%, P = 0.285) and PFS (50%, 36.4%, 27.3% vs. 68.2%, 25.6%, 12.8%, P = 0.999) were similar in the RFA group and the SR group. For patients with early recurrent tumors ≤3 cm, RFA and SR could achieve similar curative effects. However, SR was superior to RFA in terms PFS for patients with early recurrent tumors >3 cm, but the OS was similar. For all patients, RFA had significantly fewer complications and shorter hospitalization time compared with SR.
Conclusion
SR achieves better tumor control compared with RFA for patients with early rHCC (>3 cm) after SR. RFA had significantly fewer complications and shorter hospitalization time compared with SR for all patients.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. |
|